We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines

RWE studies are increasingly recognized as a regulatory pathway which accelerates the time taken to treat patients with urgent and unmet needs. It has been successfully used throughout history for the licensing of medicines, notably the development of Covid-19 vaccines and a number of cancer treatments.

RWE is at the forefront of our regulatory strategy as we seek to deliver on our goal of receiving marketing authorisations for our medicines.

We utilise existing clinical infrastructure, through collaborations with research institutions, hospital centres and government agencies, to deliver and improve patient access to our treatments.

KRN-101, is a potential solution for cancer-related anxiety, a market of over 15 million people with roughly 1 million new sufferers each year. From this initial focus, we will address broader mental health concerns reported to affect over a billion people worldwide.

We are a publicly-traded company listed on the Canadian Securities Exchange (CSE:ABRT) and Frankfurt Stock Exchange (FSE:VB50).